Main-chain imidazolium oligomer material as a selective biomimetic antimicrobial agent.
Human health has been challenged by multi-drug-resistant microorganisms for several decades. Herein, we have developed a main-chain imidazolium oligomer (IBN-1) material to combat broad spectrum of pathogenic strains, including drug-resistant Klebsiella pneumoniae, Vancomycin-resistant enterococcus, Methicillin-resistant Staphylococcus aureus and fluconazole-resistant yeast Cryptococcus neoformans, while displaying minimal hemolysis (HC(50)/MIC values over 3000) and a very high therapeutic index of 37 for killing S. aureus under inflammatory conditions in vivo.
Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, Singapore 138669, Singapore.
Lihong
L
Liu
Yuan
Y
Huang
Siti Nurhanna
SN
Riduan
Shujun
S
Gao
Yiyan
Y
Yang
Weimin
W
Fan
Yugen
Y
Zhang
D000818:Animals; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000737:chemistry* / Q000494:pharmacology*; D002478:Cells, Cultured; D003455:Cryptococcus neoformans / Q000187:drug effects; D004912:Erythrocytes / Q000187:drug effects; D006461:Hemolysis / Q000187:drug effects; D007093:Imidazoles / Q000009:adverse effects / Q000737:chemistry* / Q000494:pharmacology*; D007711:Klebsiella pneumoniae / Q000187:drug effects; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D051381:Rats; D013211:Staphylococcus aureus / Q000187:drug effects; D020713:Vancomycin Resistance
D000890:Anti-Infective Agents; D007093:Imidazoles; C029899:imidazole